Results of the study are expected to help guide development of improved diagnostics, therapeutics and more personalized clinical management strategies to combat neuropsychiatric diseases. DNA samples systematically collected
The 24-week trial was a double-blind, randomized, placebo-controlled trial conducted at 47 US study sites, evaluating 198 patients out of an originally-planned 400 patients who were suffering from
Odyssey Thera’s protein-fragment complementation assay (PCA) strategy allows for the on-pathway and off-pathway activities of compounds to be visualized and quantified directly in living human cells. Each of
The study showed a mean percent decrease in inflammatory lesions of 33.5% in patients treated with Zyflo, compared to 26.9% in the placebo group. Critical Therapeutics said that
UFT, an oral chemotherapy that already has marketing approval in approximately 60 countries, will complement Merck’s current treatment for colon cancer, Erbitux, currently approved in 39 countries around
Tarceva (erlotinib) is an oral tablet indicated for daily administration developed by OSI in collaboration with Genentech and Roche. It will now be available to patients with locally
Under the terms of the agreement, Schering-Plough will supply Pegetron (peginterferon alfa-2b powder for solution plus ribavirin 200mg capsules) as well as providing certain technical and laboratory support.
The transaction includes rights to Excedrin, Keri, Comtrex, 4-Way, Bufferin, Vagistat, No-Doz and Mineral Ice in the US and Canada. The transaction also includes rights to the US
GenCorp will receive $100 million in cash and a seller note for the further $19 million in consideration of their Rancho Cordova-based unit. Under the deal certain debts
The study established the safety of HDL therapy as a potential treatment for atherosclerosis, a disease of blood vessels caused by the build-up of cholesterol-filled plaques in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.